MedTrace Logo

COVID-19 Disease Duration and GIT Manifestations. A New Disease Severity Classification. An Egyptian Experience

NCT04554979 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 199

Last updated 2020-09-22

No results posted yet for this study

Summary

The present study conducted to correlate symptoms not only constitutional and respiratory, but GIT as a principle presentation, with laboratory markers and COVID-19 severe acute respiratory syndrome (SARS-COV2) disease outcomes, as the duration of symptoms varies substantially between patients; the investigators undertook this study to determine the optimal time to predict COVID-19 outcomes based on real-time experience.

Conditions

Interventions

DRUG

Hydroxychloroquine Pill

hydroxychloroquine 400 mg twice daily first day and maintained on 200 mg twice daily for 6 days in mild cases and 10 days in moderate cases. Also they received anticoagulants, vitamin c and zinc. In case of secondary bacterial infection, empiric antibiotics are started

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Mona M Hegazy, MD · Professor of Internal Medicine Hepatology & gastroenterology Unit. Faculty of medicine Cairo University

  • Ahmed M Abdul Ghani, MD · Lecturer of Internal Medicine Hepatology & gastroenterology Unit. Faculty of medicine Cairo University

  • Rania M Lithy, MD · Lecturer of Endemic medicine and hepatogastroenterology. Faculty of medicine Cairo University

  • Hoda M abdel-Hamid, MD · Lecturer of Respiratory medicine. Faculty of medicine Cairo University

  • Mahmoud Wahba, MD · Lecturer of Internal Medicine Division of Gastroenterology, Kasr Alainy . Faculty of Medicine, Cairo University

  • Omar Ashoush, MD · Lecturer of Internal Medicine Hepatology & gastroenterology Unit. Faculty of medicine Cairo University

  • Mohamed Tharwat Hegazy, MD · Lecturer of Internal Medicine Department, Rheumatology and Clinical Immunology unit, Faculty of Medicine, Cairo University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2020-07-15
Completion
2020-07-15

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04554979 on ClinicalTrials.gov